NRF2 expression significantly correlated with drug sensitivity in multiple ER-positive breast cancer cell lines, but not associated with pathological complete response after neoadjuvant chemotherapy in breast cancer patients regardless of subtypes. The gene discussed is NFE2L2; the disease is breast cancer.